| Knowledge-base field | Compact finding | High-value data / suggested ontology terms | Evidence type and citation |
|---|---|---|---|
| Definition and nomenclature | Neurohypophyseal diabetes insipidus is deficient hypothalamic production or neurohypophyseal release of arginine vasopressin, causing hypotonic polyuria and compensatory polydipsia. The preferred name is **arginine vasopressin deficiency (AVP-D)**; distinguish it from AVP resistance and primary polydipsia. | **MONDO:0007450**; synonym: central diabetes insipidus. Suggested HPO: Central diabetes insipidus (**HP:0000863**, present in evidence). | Clinical reviews and patient survey (pqac-00000003, pqac-00000005, pqac-00000016) |
| Epidemiology | AVP-D is rare, and population-level incidence data are limited. Acquired disease greatly exceeds congenital disease in adult clinical cohorts. | Approximate prevalence: **1 in 25,000**. Hereditary DI has been estimated at **<10%** of DI cases. | Reviews (pqac-00000002, pqac-00000006) |
| Major etiologies | Acquired causes include hypothalamic–pituitary surgery, sellar or suprasellar tumors and cysts, trauma, hemorrhage or ischemia, autoimmune or inflammatory hypophysitis, Langerhans-cell histiocytosis, germinoma, sarcoidosis, infection, congenital CNS malformations, and idiopathic disease. | In a 1,034-person survey: idiopathic **30%**, presurgical tumor/cyst **21%**, and postsurgical tumor/cyst **25%**. In 23 children with pituitary-stalk thickening, **73.9%** had germinoma and three had LCH. Adult stalk-lesion series averaged **24% neoplastic, 28% inflammatory, 11% congenital, and 37% unknown**. | Human survey, pediatric cohort, and imaging review (pqac-00000003, pqac-00000021, pqac-00000022) |
| Hallmark phenotypes | Large-volume dilute urine, excessive thirst, nocturia, dehydration, fatigue, weight loss, and hyperosmolality or hypernatremia when water access or thirst is impaired; partial AVP-D can be milder. | Survey frequencies: polyuria **90%**, polydipsia **88%**, and nocturia **78%**. Suggested HPO terms: **Polyuria**, **Polydipsia**, **Nocturia**, **Dehydration**, **Hypernatremia**, **Fatigue**, **Weight loss**, and Central diabetes insipidus (**HP:0000863**); other IDs require ontology validation. | International patient survey and clinical review (pqac-00000000, pqac-00000006) |
| Associated endocrine phenotypes | Acquired stalk or hypothalamic disease often produces combined anterior and posterior pituitary dysfunction rather than isolated AVP-D. | Survey: isolated posterior dysfunction **47%** and combined anterior/posterior dysfunction **53%**. In pediatric stalk thickening: growth-hormone deficiency **56.5%**, hyperprolactinemia **39%**, central hypothyroidism **34.8%**, and adrenal insufficiency **9%**. Suggested HPO terms require ID validation. | Human survey and pediatric cohort (pqac-00000000, pqac-00000022) |
| Causal gene and inheritance | Familial neurohypophyseal DI is primarily caused by heterozygous pathogenic **AVP** variants and usually follows fully penetrant autosomal-dominant inheritance; rare autosomal-recessive disease results from biallelic variants or a large deletion. | **AVP**, Ensembl **ENSG00000101200**; more than **70 variants** reported by 2020. Classes include missense, nonsense, frameshift, deletion, and signal-peptide defects, predominantly affecting neurophysin II. Example: **NM_000490.4:c.61T>C (p.Tyr21His; rs121964893)**. | Genetic reviews, family sequencing, and Open Targets aggregation (pqac-00000008, pqac-00000009, pqac-00000016) |
| Core familial mechanism | Mutant prepro-AVP misfolds and remains in the endoplasmic reticulum, heterodimerizes with and traps wild-type precursor, undergoes ER-associated proteasomal degradation or forms disulfide-linked fibrillar aggregates, and reduces regulated AVP secretion. Chronic ER stress, unfolded-protein response, and autophagy are implicated in progressive neuronal dysfunction; neuron loss occurs in some models but is not required for early disease. | Precursor components: 19-aa signal peptide, AVP nonapeptide, 93-aa neurophysin II, and copeptin. Suggested GO processes: protein folding, ER-associated degradation, unfolded-protein response, autophagy, regulated secretion, AVP secretion, and renal water reabsorption; IDs require validation. | In-vitro experiments and knock-in/transgenic mouse studies (pqac-00000008, pqac-00000011, pqac-00000013, pqac-00000015) |
| Downstream renal mechanism | Reduced circulating AVP decreases collecting-duct V2-receptor activation and aquaporin-2 membrane recruitment, reducing water reabsorption and producing dilute urine; intact thirst often prevents marked hypernatremia. | Suggested cell types: hypothalamic magnocellular AVP neuron and renal collecting-duct principal cell; CL IDs require validation. Suggested processes: AVPR2 signaling, AQP2 trafficking, and water homeostasis. | Physiological review (pqac-00000005) |
| Initial diagnostic confirmation | Confirm true hypotonic polyuria, exclude osmotic diuresis and electrolyte or renal causes, and measure serum sodium, plasma osmolality, and urine osmolality. | Polyuria: **>50 mL/kg/day or >3 L/day**. With hypernatremia, urine osmolality **<300 mOsm/kg** supports an AVP disorder, whereas **>700 mOsm/kg** indicates preserved AVP action. Acute postoperative criteria include polyuria, urine osmolality **<300 mOsm/kg**, and plasma osmolality **>300 mOsm/kg** or sodium **>145 mmol/L**. | Clinical guidance and review (pqac-00000001, pqac-00000002) |
| Dynamic testing | Water deprivation followed by desmopressin distinguishes AVP-D from AVP resistance, but performs poorly in partial disease or chronic primary polydipsia and can cause dehydration. Stimulated copeptin is the preferred modern discriminator where expertise is available. | Traditional water-deprivation accuracy approximately **70% overall** and **41% for primary polydipsia**. Baseline copeptin **>21.4 pmol/L** supports AVP resistance. Arginine-stimulated thresholds under the predefined protocol: **<2.4 pmol/L** complete AVP-D, **2.4–3.8 pmol/L** partial AVP-D, and **>3.8 pmol/L** primary polydipsia. | Diagnostic reviews and prospective-test protocol evidence (pqac-00000006, pqac-00000017) |
| Imaging and etiologic work-up | Contrast-enhanced hypothalamic–pituitary MRI evaluates the posterior-pituitary bright spot, stalk thickness, hypothalamus, and sellar or suprasellar masses. Isolated stalk thickening requires serial endocrine and MRI surveillance because germinoma or LCH can emerge later. | Pediatric CDI study: etiologic diagnosis at presentation **28.2%**, an additional **13% within 2.5 years**, and permanent anterior deficits **53%**. Suggested surveillance: MRI every six months for two years and again during year three or annually according to risk; pituitary testing every six months for 2–3 years, then annually. | Prospective pediatric cohort and imaging reviews (pqac-00000023, pqac-00000024) |
| Standard treatment | **Desmopressin (dDAVP)**, a selective V2-receptor agonist, replaces AVP's antidiuretic action; oral formulations generally have the best tolerability and safety profile. Ensure free access to water and treat the underlying lesion where possible. | Suggested intervention term: desmopressin therapy; NCIT identifier requires validation. | Recent treatment reviews (pqac-00000003, pqac-00000007) |
| Treatment safety | Continuous antidiuresis plus excess fluid intake can cause dilutional hyponatremia; missed or delayed dDAVP, fasting, or restricted water can cause severe hypernatremic dehydration. Planned intermittent aquaresis reduces risk. | Survey: outpatient hyponatremia **22%**, dysnatraemia requiring admission **35%**, and hypernatremia requiring admission **15%**; desmopressin escape was associated with lower hyponatremia (**OR 0.55, 95% CI 0.39–0.77; p=0.0006**). NHS England recorded **471** incidents, including **76 dose omissions** and **four deaths** from severe dehydration. | Human survey and safety-event data (pqac-00000000, pqac-00000004) |
| Prognosis and quality of life | Isolated hereditary AVP-D is generally compatible with long-term survival when water and dDAVP are reliably available. Morbidity and mortality in acquired disease are driven chiefly by the underlying lesion, hypothalamic injury, associated pituitary deficits, and dysnatraemia. | In the international survey, **64%** reported reduced quality of life and **36%** psychological or recognized psychological changes. In craniopharyngioma, DI and hypopituitarism were negative prognostic factors; childhood-onset standardized mortality ratio was **17 (95% CI 6.3–37)**. | Human survey and population-based craniopharyngioma cohort (pqac-00000000, pqac-00000026) |
| Models and experimental therapy | Brattleboro rats carry an Avp defect and reproduce polyuria and polydipsia; AVP-mutant knock-in mice model ER retention, progressive hormone deficiency, and variable neuronal loss. Viral AVP replacement in magnocellular neurons provides preclinical proof of concept but is not an established human therapy. | Suggested model annotations: Brattleboro rat, AVP-mutant knock-in mouse, neuronal cell-expression model, and ERAD-deficient mouse. Human gene, cell, RNA, or CRISPR therapy is not established. | Rodent and cellular mechanistic evidence (pqac-00000011, pqac-00000013, pqac-00000014) |
| Current trials and emerging research | Current research emphasizes easier copeptin stimulation and whether concomitant oxytocin deficiency contributes to psychological, social, and sexual morbidity after hypothalamic–pituitary injury. | Examples: **NCT05890690**, oral-urea/copeptin, completed, 48 participants; **NCT06036004**, oxytocin substitution, phase 2, recruiting, 112 participants; **NCT04789148**, intranasal oxytocin, phase 1, recruiting, 40 participants; **NCT03572166**, arginine-stimulated copeptin, completed, 177 participants. | Clinical-trial registry records and recent diagnostic evidence (pqac-00000017) |


*Table: Compact evidence table covering neurohypophyseal diabetes insipidus nomenclature, causes, phenotypes, genetics, mechanisms, diagnosis, treatment, prognosis, models, and emerging trials. Statistics are labeled by evidence type, while ontology terms lacking verified identifiers are explicitly marked for validation.*